Clinical Trial Update: Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of Benmelstobart, Anlotinib, and SBRT for hepatocellular carcinoma patients who failed first-line targeted therapy; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Benmelstobart

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Hepatocellular Carcinoma (HCC), First-line Targeted Therapy Failure | Phase 2 | Status: NOT_YET_RECRUITING